Combination antifungal therapy: the new frontier
- PMID: 17661650
- DOI: 10.2217/17460913.2.2.115
Combination antifungal therapy: the new frontier
Abstract
The past decade has seen a significant increase in the incidence of invasive fungal infections. The antifungal armamentarium for the treatment of serious fungal infections remains limited. A possible approach to overcoming antifungal drug resistance and high mortality rates seen in severe fungal infections is to combine two or three classes of antifungals, especially if the drugs have different mechanisms of action. Combinations of new agents along with more traditional antifungals have now been shown to possess some synergistic or at least additive activity against many fungi in in vitro and animal studies. On the other hand, caution is still needed since some antifungal combinations have also demonstrated antagonistic activity. Well-controlled clinical trials are still required to define the most efficacious antifungal regimen. Furthermore, these trials should also evaluate the side-effect potential of combination regimens and the pharmacoeconomic impact these regimens may have.
Similar articles
-
Clinical practice: combination antifungal therapy for mold infections: much ado about nothing?Clin Infect Dis. 2008 Jun 15;46(12):1889-901. doi: 10.1086/588475. Clin Infect Dis. 2008. PMID: 18466092 Review.
-
Combination antifungal therapy against Candida species: the new frontier--are we there yet?Med Mycol. 2003 Oct;41(5):355-68. doi: 10.1080/13693780310001616528. Med Mycol. 2003. PMID: 14653512 Review.
-
Antifungal combinations.Methods Mol Med. 2005;118:143-52. doi: 10.1385/1-59259-943-5:143. Methods Mol Med. 2005. PMID: 15888940
-
Current status of antifungal resistance and its impact on clinical practice.Br J Haematol. 2014 Aug;166(4):471-84. doi: 10.1111/bjh.12896. Epub 2014 Apr 18. Br J Haematol. 2014. PMID: 24749533 Review.
-
New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.Expert Rev Anti Infect Ther. 2009 Oct;7(8):981-98. doi: 10.1586/eri.09.67. Expert Rev Anti Infect Ther. 2009. PMID: 19803707 Review.
Cited by
-
Synergistic activity of the combination of falcarindiol and itraconazole in vitro against dermatophytes.Front Cell Infect Microbiol. 2023 May 3;13:1128000. doi: 10.3389/fcimb.2023.1128000. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37207188 Free PMC article.
-
A Novel Dual-Targeted α-Helical Peptide With Potent Antifungal Activity Against Fluconazole-Resistant Candida albicans Clinical Isolates.Front Microbiol. 2020 Sep 30;11:548620. doi: 10.3389/fmicb.2020.548620. eCollection 2020. Front Microbiol. 2020. PMID: 33101226 Free PMC article.
-
In Vitro Activity of Amphotericin B in Combination with Statins against Clinical and Environmental Rhizopus oryzae Strains.Iran J Public Health. 2019 May;48(5):943-948. Iran J Public Health. 2019. PMID: 31523652 Free PMC article.
-
Inhibitory effects of cysteine and cysteine derivatives on germination of sporangiospores and hyphal growth of different Zygomycetes.Mycopathologia. 2009 Sep;168(3):125-34. doi: 10.1007/s11046-009-9204-x. Epub 2009 Apr 19. Mycopathologia. 2009. PMID: 19381868
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous